Add like
Add dislike
Add to saved papers

Trifocal Intraocular Lens Selection: Predicting Visual Function From Optical Quality Measurements.

PURPOSE: To apply in vitro quality metrics to assess and compare three trifocal intraocular lenses (IOLs).

METHODS: The optical performance of the AT LISA tri 839MP (Carl Zeiss Meditec AG), AcrySof IQ PanOptix (Alcon Laboratories, Inc), and TECNIS Synergy (Johnson & Johnson Vision) was compared. The modulation transfer function (MTF) metrics were obtained using an optical bench set-up. A polychromatic light source and a model cornea inducing chromatic and spherical aberrations were used to mimic in vivo characteristics. The area under the MTF was calculated at each defocus position, which served as a parameter in a nonlinear formula applied to predict postoperative visual acuity (VA).

RESULTS: All of the studied IOLs had a predicted VA of 0.2 logMAR or better throughout the range of 0.00 to -3.00 diopters (D). Simulated VA differences between the IOLs were negligible (< 0.01 logMAR) at the far point. Although the three models were comparable at -1.00 D, at -2.00 D the AT LISA tri 839MP's VA was 0.06 and 0.08 logMAR worse than with the TECNIS Synergy and AcrySof IQ PanOptix, respectively. At near focus, the AcrySof IQ PanOptix's estimated VA was 0.06 logMAR (40 cm); for the AT LISA tri 839MP and TECNIS Synergy, it was 0.06 and 0.03 logMAR, respectively, at 36 cm.

CONCLUSIONS: Although simulated distance VA was comparable between the studied models, differences can be found in the intermediate focus' position and quality and the expected reading distance. Therefore, simulations of defocus curves from optical quality metrics provide insight into IOL characteristics and highlight differences between the IOLs, which may guide the selection of a trifocal lens based on patients' needs. [ J Refract Surg . 2023;39(2):111-118.] .

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app